Impact Factor
3.26
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.86
250 total citations
h5-index
20
h5 depth signal
Cited share
78.2%
68 of 87
Total citations
250
Citation footprint
Metric signal
3.19
External metric anchor
Self-citation
0.0%
0 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
149
China
67
Germany
41
Japan
37
Italy
31
Citing Fields of Research
Pharmacology & Toxicology
96
Cardiology
37
Cancer Drugs
31
Anesthetic & Pain Medicine
31
Oncology
29
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,280
Articles tracked across the journal lifetime
Indexed publication set
87
68 cited publications
Last 12 months
27
3.0 publications/month
Open access share
100.0%
27 OA publications in the last year
Leading citing country
United States
149 citing publications
Leading citing field
Pharmacology & Toxicology
96 citing publications
Latest tracked publication
26 September 2026
10 recent records available
Coverage & Indexing History
v1n1, Jan. 1999-
v1n1, Jan. 1999-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Pharmacology & Toxicology
Hematology
Antibiotic & Antibacterial Agents
Anesthetic & Pain Medicine
Drug Delivery Systems
Cancer Drugs
Broad Categories
Drug Therapy
Pharmacology
Separation Techniques
Hematology
Antibiotic & Antibacterial Agents
Cardiology
Chronobiology
Medical Ethics
MeSH Descriptors
Drug Evaluation
Drug Industry
Drug Therapy
Drugs, Investigational
Research
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s40268-026-00551-y
Open DOI
Anti-Fungal and Toxicology Assessment of ISFP10, an Inhibitor of Fungal Phosphoglucomutase (PGM)
Background and Objective The novel small molecule ISFP10 inhibits fungal phosphoglucomutase (PGM) activity in Aspergillus fumigatus and Pneumocystis spp. With 50-fold selectivity over the human isoform, conferred by a conserved cysteine ...
02
03
04
DOI 10.1007/s40268-026-00547-8
Open DOI
Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study
Background Gabapentin is effective for treating post-herpetic neuralgia and neuropathic pain by stabilizing nerve activity through blocking calcium channels and reducing neurotransmitter release. Gabapentin is available in immediate-rele...
05
DOI 10.1007/s40268-026-00546-9
Open DOI
Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation
High-altitude illness (HAI) poses health risks to individuals at high altitudes, and acetazolamide (ACZ) is the only Food and Drug Administration (FDA)-approved prophylactic drug. Conventional immediate-release (IR) tablets and extended-...
06
DOI 10.1007/s40268-026-00548-7
Open DOI
Optimizing Drug-Resistant Epilepsy Management: Cenobamate’s role in the Surgery/Neuromodulation Pathway
07
DOI 10.1007/s40268-026-00544-x
Open DOI
A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors
Neuroendocrine tumors are a rare and heterogeneous group of neoplasms that frequently cause carcinoid syndrome, characterized by diarrhea, flushing, and carcinoid heart disease. A recent therapy for carcinoid syndrome involves inhibition...
08
DOI 10.1007/s40268-026-00545-w
Open DOI
Ustekinumab in the Management of Perianal Fistulizing Crohn’s Disease: Current Evidence and Practical Strategies
Perianal fistulizing Crohn’s disease (PFCD) is a severe and complex manifestation associated with high morbidity and limited treatment durability. Ustekinumab is a monoclonal antibody targeting the interleukin-12/23 pathway, which is inv...
09
10
Bibliographical & Catalog Notes
Title from cover.
Print issues ceased with v. 9, no. 6 (2008)
None published 2000-2001.
Publication suspended from 2008-2009.
Also issued online.